Home > Companies > Esperion - The Lipid Management Company

Esperion - The Lipid Management Company

esperion.com

Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease; the leading cause of death around the world.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

A Tool for Deprescribing in Long-Term Care

Webinar

2024 ISPE Facilities of the Future Conference

Conference

Related News

Business Insights

FOSUN PHARMA AND INSILICO MEDICINE ANNOUNCE A STRATEGIC, AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION TO JOINTLY ADVANCE MULTIPLE TARGETS

Insilico Medicine | January 18, 2022

Shanghai Fosun Pharmaceutical Co., Ltd, a leading innovation-driven international healthcare group in China and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. This strategic collaboration includes an AI-driven drug discovery research and development (...

Pharmacy Market

TRANSACTION DATA SYSTEMS ACHIEVES KLOUDSCRIPT, A CLOUD-BASED SPECIALTY PHARMACY SOLUTION

Transaction Data Systems | November 25, 2020

Exchange Data Systems (TDS), the pioneer in drug store programming answers for the network drug store market, today reported the obtaining of KloudScript, a strength drug store care arrangement. Right now 39% of network drug stores apportion a type of strength prescriptions, agreeing the National Community Pharmacy Association. Interest for strength meds has been consistently ascending to treat explicit sickness states and the constantly sick. With the maturing populace and the ex...

Business Insights

CORDENPHARMA COMPLETES ACQUISITION OF THREE MANUFACTURING FACILITIES FROM VIFOR PHARMA

CordenPharma | February 01, 2022

CordenPharma, a leading, full-service Contract Development & Manufacturing Organization supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. in Switzerland, and Corden Pharma Lisbon S.A. in Portugal. "We welcome the three sites and their employees as new members to the Cor...

Business Insights

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Business Insights